Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + IL-15 in ccRCC
NCT04150562Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2020
- Primary completion
- Jul 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin-15 in clear cell renal cell carcinoma (ccRCC), sponsored by National Cancer Institute. Started May 2020; status: terminated.
02
Drugs
recombinant human interleukin-15
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04150562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150562.